OBIO · NASDAQ · Biotechnology

Orchestra BioMed (OBIO)

Develops partnership-enabled device therapies for hypertension and artery disease.

$4.95
At close+0.05 (+1.02%)

Something off on this page? Send us feedback.

Next report
Nov 9, 2026
estimated · in 67 days
EPS estimate
−$0.41
Revenue estimate
$133.0K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Apr '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.43−$0.50−$0.40$0.26−$0.33−$0.38−$0.38Pending
Estimate−$0.43−$0.51−$0.38−$0.38−$0.40−$0.39−$0.35−$0.41
Surprise0.0%+2.0%−5.3%+168.4%+17.5%+3.1%−8.6%

RevenueReportedEstimate

Apr '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$253.0K$836.0K$861.0K$30.9M$110.0K$88.0K$88.0KPending
Estimate$522.3K$778.8K$741.4K$931.0K$918.7K$137.7K$137.7K$133.0K
Surprise−51.6%+7.3%+16.1%+3,220.8%−88.0%−36.1%−36.1%

History

DateEstimateReportedSurprise
Nov 2026−$0.41
Aug 2026−$0.35−$0.38−8.6%
Aug 2026−$0.39−$0.38+3.1%
May 2026−$0.40−$0.33+17.5%
Mar 2026−$0.38$0.26+168.4%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
Apr 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Jan 2023
Dec 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 9, 2026−$0.41$133.0K
Aug 11, 2026−$0.35−$0.38−8.6%$137.7K$88.0K−36.1%+0.5%
Aug 10, 2026−$0.39−$0.38+3.1%$137.7K$88.0K−36.1%−1.4%
May 12, 2026−$0.40−$0.33+17.5%$918.7K$110.0K−88.0%0.0%
Mar 12, 2026−$0.38$0.26+168.4%$931.0K$30.9M+3,220.8%−4.1%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Nov 10, 2025
Aug 12, 2025
Apr 2, 2025
Mar 26, 2025
Nov 12, 2024
Aug 12, 2024
May 13, 2024
Mar 27, 2024
Nov 13, 2023
Aug 10, 2023
May 12, 2023
Jan 25, 2023
Dec 16, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021